Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 47

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 1
Chunk 47
---
 acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies.  Additionally, the segment provides products and consumables used to filter and remove contaminants from a variety of liquids and gases in many end-market applications.

As discussed in Note 8 to the accompanying Consolidated Condensed Financial Statements, during the third quarter of 2025, the Company reorganized and integrated certain businesses within its Life Sciences segment to better serve the Company’s customers in new market segments and to respond to current market conditions.  The life sciences instruments business includes the flow cytometry and lab automation solutions business, the mass spectrometry business and the microscopy business.  The life science consumables business includes the genomic medicines businesses and the protein consumables business.

Life Sciences Selected Financial Data 

 Three-Month Period EndedNine-Month Period Ended($ in millions)September 26, 2025September 27, 2024September 26, 2025September 27, 2024Sales$1,792 $1,782 $5,249 $5,297 Operating profit222 35 184 503 Depreciation47 44 137 123 Amortization of intangible assets154 147 453 428 Operating profit as a % of sales12.4 %2.0 %3.5 %9.5 %Depreciation as a % of sales2.6 %2.5 %2.6 %2.3 %Amortization as a % of sales8.6 %8.2 %8.6 %8.1 %

Sales Growth (Decline) and Core Sales Decline

% Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period% Change Nine-Month Period Ended September 26, 2025 vs. Comparable 2024 PeriodTotal sales growth (decline) (GAAP)0.5 %(1.0)%Impact of:Acquisitions— %(1.0)%Currency exchange rates (1.5)%(0.5)%Core sales decline (non-GAAP)(1.0)%(2.5)%

Price increases in the segment contributed 1.0% and 0.5% to the change in sales on a year-over-year basis during the three and nine-month periods ended September